NCT07600996Completed
Cerebrospinal Fluid Mitochondrial Biomarkers in Ischemic Stroke and Alzheimer Disease
A Prospective Observational Study of Cerebrospinal Fluid Mitochondrial Biomarkers Measured by Flow Cytometry in Patients With Ischemic Stroke and Alzheimer Disease Controls
Source: ClinicalTrials.gov · Last updated 9 Sept 2026
Brief summary (registry, in English)
This prospective observational study aims to investigate cerebrospinal fluid mitochondrial biomarkers in patients with ischemic stroke and Alzheimer disease controls who undergo diagnostic lumbar puncture for clinical indications at Xuanwu Hospital, Capital Medical University. Residual cerebrospinal fluid samples will be analyzed by flow cytometry to quantify mitochondrial content, mitochondrial membrane potential, and cellular or vesicular source-related markers. The flow cytometry panel will include MitoTracker, JC-1, and membrane-associated markers including CD45, CD41, CD24, vWF, and EAAT1. In patients with ischemic stroke, the study will further examine whether cerebrospinal fluid mitochondrial measurements are associated with neurological severity and functional outcomes, including admission and discharge NIHSS scores and the 90-day modified Rankin Scale score. Alzheimer disease patients undergoing diagnostic lumbar puncture will serve as disease controls for biomarker comparison.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 40 (actual)
- First submitted
- 15 May 2026
- Start date
- 1 Mar 2026
- Primary completion date
- 31 May 2026
- Lead sponsor
- Capital Medical University
- Diseases
- Stroke, Alzheimer disease
- NCT number
- NCT07600996
What you commit to
- Study type: Observational
- Participants enrolled: 40
- From 1 Mar 2026 to the primary completion date, 31 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Lumbar puncture performed solely for research purposes rather than clinical indication.
- Insufficient residual cerebrospinal fluid volume for research flow cytometry analysis.
- Grossly bloody or severely contaminated cerebrospinal fluid sample that precludes reliable flow cytometry analysis.
- Known central nervous system infection, malignant meningitis, or other inflammatory or neoplastic condition that, in the investigator's judgment, may substantially confound cerebrospinal fluid mitochondrial measurements.
- Inability to obtain informed consent from the participant or legally authorized representative.
- Missing key clinical outcome data, including admission NIHSS, discharge NIHSS, or planned 90-day mRS follow-up for ischemic stroke participants.
- Any condition judged by the investigator to make the participant unsuitable for inclusion in the study.
Who the study is looking for
- Age 18 years or older. Patients treated at Xuanwu Hospital, Capital Medical University between March 2026 and May 2026.
- Diagnosis of ischemic stroke or Alzheimer disease according to standard clinical diagnostic criteria.
- Diagnostic lumbar puncture performed for clinical indications as part of routine medical care.
- Availability of residual cerebrospinal fluid after completion of clinically required testing.
- Ability to provide written informed consent, or availability of a legally authorized representative to provide consent when appropriate.
- For ischemic stroke patients, availability of baseline neurological assessment and planned follow-up for 90-day modified Rankin Scale assessment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Xuanwu Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.